22 December 2025VideosBiotechnologyDirk Buehler, Maiwald

WATCH: “Try and see” – an underestimated standard for obviousness before the EPO?

Dirk Buehler, Maiwald, discusses how the “try and see” standard is applied before the EPO and its relevance in pharma and biotech cases.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

4 June 2026 The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs.

Biotechnology

Gilead to pay up to $5bn for antibody-drug conjugates push

8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.

Biotechnology

Closing the women's health gap offers ‘benefits for all’

7 April 2026 On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.

More features

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

Heated LNP litigation puts Moderna and Acuitas in the spotlight

Medtech company sues over seven patents for incontinence products

10x Genomics settles suit with rival and targets DNA sequencing startup

WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular

Moderna loses key mRNA patent in European vaccine fight

Ligand buys biotech in $739m cash deal with litigation sweetener

CureVac targets Moderna with 10-patent suit over Spikevax

WATCH: “Try and see” – an underestimated standard for obviousness before the EPO?

More on this story

Editor's picks

Editor's picks

More features